LFSA – Africa! “Rare genetic disorder that helps cancer run in families”
Lakita at the LFSA's Youth Workshop in 2023 LFSA - Africa's Media Relations Specialist Joel Magu has published another article
Facing Sarcoma: Science, Loss, & the Power of Advocacy Podcast
Hosted by Upstate Medical University during Sarcoma Awareness Month, LFSA’s Kathy Higgins, Director of Education and Awareness, sat down with orthopedic
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who
Attention Young Adults between 18-29 living in the US of A!
Would you like to participate in a research study at the National Cancer Institute that is developing a mental health
LFSA Co-Founder Debbie Soprano Honored by Boston Children’s Hospital
The Li-Fraumeni Syndrome Association (LFSA) is proud to announce that Co-Founder and Board Member Debbie Soprano has been recognized
LFSA – Africa! “Rare genetic disorder that helps cancer run in families”
Lakita at the LFSA's Youth Workshop in 2023 LFSA - Africa's Media Relations Specialist Joel Magu has published another article in Kenyan
LFSA – Africa! “Rare genetic disorder that helps cancer run in families”
Lakita at the LFSA's Youth Workshop in 2023 LFSA - Africa's Media Relations Specialist Joel Magu
Facing Sarcoma: Science, Loss, & the Power of Advocacy Podcast
Hosted by Upstate Medical University during Sarcoma Awareness Month, LFSA’s Kathy Higgins, Director of Education and Awareness,
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations
Annual Whole-Body Imaging Contributes to Early Cancer Detection in Patients With Li-Fraumeni Syndrome
Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized cancers among individuals with Li-Fraumeni syndrome (LFS).
Seeking Participants for the INFORM Research Study
Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a first-of-its-kind blood test. This test will predict
Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Just published by American Association for Cancer Research (AACR) is the updated version of the “Toronto Protocol,” the widely recognized screening recommendations for Li-Fraumeni
Li-Fraumeni syndrome: predicting cancer risk more precisely
The two MHH researchers Lucas John Müntnich and Professor Christian Kratz refer to the cluster analysis of the study, according to which cancer-free survival
Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome
UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming to assess the time to
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different phenotypes of the Li-Fraumeni Syndrome.
